Discriminating between latent and active tuberculosis with multiple biomarker responses. - Wikidata - wikimedia - TriplyDB

Discriminating between latent and active tuberculosis with multiple biomarker responses.

Discriminating between latent and active tuberculosis with multiple biomarker responses.

http://www.wikidata.org/entity/Q34958633

about

The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use Point-of-care diagnosis of tuberculosis: past, present and future Evaluation of the filter paper IP-10 tests in school children after exposure to tuberculosis: a prospective cohort study with a 4-year follow-up A simple method to quantitate IP-10 in dried blood and plasma spots Multiple cytokines are released when blood from patients with tuberculosis is stimulated with Mycobacterium tuberculosis antigens Current developments and future perspectives for TB diagnostics.Diminished plasma levels of common γ-chain cytokines in pulmonary tuberculosis and reversal following treatment The human antibody response to the surface of Mycobacterium tuberculosis.Characterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice.Potential of host markers produced by infection phase-dependent antigen-stimulated cells for the diagnosis of tuberculosis in a highly endemic area Mycobacteria-Specific Cytokine Responses Detect Tuberculosis Infection and Distinguish Latent from Active Tuberculosis.Evaluation of the diagnostic potential of IP-10 and IL-2 as biomarkers for the diagnosis of active and latent tuberculosis in a BCG-vaccinated population Plasma heme oxygenase-1 levels distinguish latent or successfully treated human tuberculosis from active disease.Utility of host markers detected in Quantiferon supernatants for the diagnosis of tuberculosis in children in a high-burden setting.Discrimination between active and latent tuberculosis based on ratio of antigen-specific to mitogen-induced IP-10 production IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection.A single-nucleotide-polymorphism real-time PCR assay for genotyping of Mycobacterium tuberculosis complex in peri-urban Kampala.Cytokine and Antibody Based Diagnostic Algorithms for Sputum Culture-Positive Pulmonary Tuberculosis.Multicytokine detection improves latent tuberculosis diagnosis in health care workers Heme Oxygenase-1 Regulation of Matrix Metalloproteinase-1 Expression Underlies Distinct Disease Profiles in Tuberculosis.Cytokine Patterns in Tuberculosis Infection; IL-1ra, IL-2 and IP-10 Differentiate Borderline QuantiFERON-TB Samples from Uninfected Controls.Spontaneous latency in a rabbit model of pulmonary tuberculosis.Prokaryotic expression and in vitro functional analysis of IL-1β and MCP-1 from guinea pig.Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection.IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions.Diagnostic accuracy of IL-2 for the diagnosis of latent tuberculosis: a systematic review and meta-analysis.Point-of-care diagnostics, a major opportunity for change in traditional diagnostic approaches: potential and limitations.Integrating knowledge of Mycobacterium tuberculosis pathogenesis for the design of better vaccines.Diagnostic performance of a seven-marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB.Distinguishing Latent from Active Mycobacterium tuberculosis Infection Using Elispot Assays: Looking Beyond Interferon-gamma.MIGRAs: are they the new IGRAs? Development of monokine-amplified IFN-γ release assays.CXCL9, a promising biomarker in the diagnosis of chronic Q fever.Role of QuantiFERON-TB Gold antigen-specific IL-1β in diagnosis of active tuberculosis.Auxiliary diagnostic value of monocyte chemoattractant protein-1 of whole blood in active tuberculosis.Monocyte Chemotactic Protein 1 in Plasma from Soluble Leishmania Antigen-Stimulated Whole Blood as a Potential Biomarker of the Cellular Immune Response to Leishmania infantum.Plasma antibody profiles in non-human primate tuberculosis.Use of QuantiFERON®-TB Gold in-tube culture supernatants for measurement of antibody responses.Potential immunological biomarkers for detection of Mycobacterium tuberculosis infection in endemic setting, Ethiopia.Africa-wide evaluation of host biomarkers in QuantiFERON supernatants for the diagnosis of pulmonary tuberculosis.What steps do we need to take to improve diagnosis of tuberculosis in children?

P2860

Q24599103-BBDBBA29-4BD7-45BA-9A6F-5FB8AB66E675 Q27004667-0DCB99C5-C1AB-4786-A148-B9C9B733D983 Q28710158-821B9674-DE61-442A-8CCA-2F24AFC51E3C Q28727912-82C5E522-D9A4-435F-9823-893ECDD01009 Q28742421-C3FA6311-5035-49D2-8DA4-C13B949F2C0B Q30410962-204190D3-90FC-4E6F-80A2-3EE22BFEB002 Q33610319-5AD8C5EC-C4AD-4399-AC2E-762F648AA9B4 Q33740190-C82180BF-C321-44B8-9B0C-AC0B86C8DC6B Q33826578-B1E24C98-88EB-448E-8001-0BAF979A85E9 Q34302593-D610F649-C76E-4F7C-B073-C1E45B8A407D Q34478705-75F83332-FA60-4B33-B1C2-3B0106857A2F Q34525238-45A5438F-35F6-4284-82E4-529B027CCF3F Q34720679-0A3242AE-ECAC-4CEE-8105-195120FFC752 Q34731357-8EB1CBEA-0CE4-4552-BC87-8E9476DCE434 Q34983098-70D60A9A-206A-4835-A9B0-1A70969ADE94 Q35188912-9252B8DC-2CFD-43F7-ADAD-D1A2C7840DFD Q35794156-42941320-6692-453C-B4B4-67A8CC1D650C Q35870599-C30B45CB-6B44-4C68-B11C-FFF4C97E6E06 Q35943027-1E71E6AB-065D-44BD-8E42-338230E734C9 Q36031524-B553A546-1CFD-446C-A7A0-25ECD1F93C9D Q36148431-582E0732-64E6-49B4-963E-D18F18DDE7F3 Q36355577-428CAC8A-3318-4A83-A77F-DB69065F7160 Q36675666-AD65E616-57C7-4C1E-AD3F-97B066D29B4E Q37611851-28A66C38-C3C6-4586-8713-AEC3DA2F4D54 Q37988577-C2B4B396-5F72-4395-B59F-02471CCFCD72 Q38226017-E8A9006D-9418-440A-A7CA-9ED7DEB18B74 Q38258595-EBF16DCA-F623-4CEB-82A5-CB5F819EFF57 Q38620366-AEB3AC6E-8182-4396-A5BD-524EF99312CC Q38854712-F0F0C860-46DA-4F17-9293-A8C8B99E66FF Q39525399-60322857-E15D-4EAF-98E2-C1A0D2C23E5A Q39636573-8C62BA67-E687-499F-81BD-5A84C50D2453 Q40043965-59E0752C-2BA3-4F52-821A-AE64E2BAA7FF Q41601094-F7DA5D95-78FB-420A-96CF-677FFD611527 Q42067111-E29071DC-9936-4B16-B58E-BBF1443F8D1F Q42369754-F2A58904-A38C-4D57-B1A6-E58201E03869 Q43725228-86D97C90-C1BF-499C-B279-B22923FBEDFF Q46172607-A0B99A28-E1D6-4D36-8030-D6CF5E5D66D6 Q47195407-F77D3E3B-D9EA-443C-93C0-40385F5B0635 Q49513549-2D750E99-652A-45EA-BB95-210F8DFD3087 Q50852169-97043D07-315B-49D8-95F6-A9DEC1284D85

P2860

Discriminating between latent and active tuberculosis with multiple biomarker responses.

http://www.wikidata.org/entity/Q34958633

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Discriminating between latent and active tuberculosis with multiple biomarker responses.

@ast

Discriminating between latent and active tuberculosis with multiple biomarker responses.

@en

Discriminating between latent and active tuberculosis with multiple biomarker responses.

@nl

type

label

Discriminating between latent and active tuberculosis with multiple biomarker responses.

@ast

Discriminating between latent and active tuberculosis with multiple biomarker responses.

@en

Discriminating between latent and active tuberculosis with multiple biomarker responses.

@nl

prefLabel

Discriminating between latent and active tuberculosis with multiple biomarker responses.

@ast

Discriminating between latent and active tuberculosis with multiple biomarker responses.

@en

Discriminating between latent and active tuberculosis with multiple biomarker responses.

@nl

P1433

Q34958633-C1C83895-4F3B-47A7-8383-C726184BDC3B

P1476

Q34958633-CD797B0C-D6BD-4015-AD74-D8F89D980EF1

P2093

Q34958633-0E397D86-F483-4649-8534-5B24FAFD2580

Q34958633-7E5D142C-7E99-4A96-82D0-907BF3831E2F

Q34958633-92F42AA9-34E4-4007-BE3C-D70647CB89CE

Q34958633-96824317-17AE-459F-84CC-65F4B64DD61F

Q34958633-AD66DC30-BB61-4C76-BC02-9B4DC1C6AA08

Q34958633-C23451D6-B8A1-47F7-854C-8AB691951A42

P2860

Q34958633-0D86F555-2047-4AED-A600-D816FF704F66

Q34958633-1CA804D1-7769-4605-B724-88AEB9BCDF31

Q34958633-1DF56C22-144A-479A-A824-744B030C7261

Q34958633-2997D418-9E35-4594-AE11-14AB2742AC35

Q34958633-47402551-872D-4482-B0FF-B167C1F32639

Q34958633-4EEBCCE6-9618-4BF6-9D20-A0FC190FFBBD

Q34958633-5735E0EB-78B0-49C8-8B47-0D2B62F77BCF

Q34958633-5AA6329D-78FF-4001-B250-2E18879AB5E7

Q34958633-5BD7AD78-36EF-4716-8136-0D7C76C9C97D

Q34958633-5F4C6815-8D70-40F9-B98F-D0085D1626ED

P304

Q34958633-E31B4138-9F2D-4E72-8395-2A4D0FCBF14C

P31

Q34958633-D86677C0-FFDF-44D1-909A-8FEE70DDA168

P356

Q34958633-C2FBD88C-A0D7-4657-AE79-EF75C430B954

P433

Q34958633-8C2DD793-F052-4871-A843-4B180550E9BE

P478

Q34958633-A0C7A41B-2A91-4389-A286-E1DC5D14951C

P50

Q34958633-749639E5-E924-4C4D-BCA5-DB74EEC844C1

Q34958633-A69B8EB4-97AD-4ED0-9DC9-79967E8D02F7

Q34958633-E37F0CE0-BC8B-4C4E-A30A-32AB1A2F7601

P577

Q34958633-EC2866D8-F7FD-4B03-BC76-9F14D2A41B37

P5875

Q34958633-61654CE1-84C3-47BE-ADBE-990063062349

P698

Q34958633-B67398D3-7257-4A46-90D6-E3E78A1282A7

P921

Q34958633-71BDE3BD-89D6-4963-B95F-F9C840291275

Q34958633-EA0A4B91-5EB1-4E39-A40D-073A68675134

P932

Q34958633-BA185026-D860-49DC-B0FA-C0D0C4DB4B81

P356

J.TUBE.2011.02.006

P1433

P1476

Discriminating between latent and active tuberculosis with multiple biomarker responses

@en

P2093

Ann Mosher

http://www.w3.org/2001/XMLSchema#string

Emily Cadogan

http://www.w3.org/2001/XMLSchema#string

Emily Hecker

http://www.w3.org/2001/XMLSchema#string

Kouros Owzar

http://www.w3.org/2001/XMLSchema#string

Marc Frahm

http://www.w3.org/2001/XMLSchema#string

Neela D Goswami

http://www.w3.org/2001/XMLSchema#string

P2860

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis

Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis

Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This st

Decay kinetics of an interferon gamma release assay with anti-tuberculosis therapy in newly diagnosed tuberculosis cases

Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons?

Advances in the diagnosis and treatment of tuberculosis.

IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay.

Joint effect of MCP-1 genotype GG and MMP-1 genotype 2G/2G increases the likelihood of developing pulmonary tuberculosis in BCG-vaccinated individuals.

A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with increased susceptibility to pulmonary tuberculosis.

P304

250-256

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TUBE.2011.02.006

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

91

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50363433

http://www.w3.org/2001/XMLSchema#string

P698

21393062

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

3090479

http://www.w3.org/2001/XMLSchema#string